Background. Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce health-related quality of life. Objective. The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) on NMS in APD. Methods. INSIGHTS was a phase 3b, open-label, randomized, multicenter study in patients with APD (LCIG or OMT, 26 weeks) (NCT02549092). Primary outcomes assessed were total NMS (NMS scale (NMSS) and PD sleep scale (PDSS-2)). Key secondary outcomes included the Unified PD Rating Scale (UPDRS) Part II, Clinical Global Impression of Change (CGI-C), and PD Questionnaire-8 (PDQ-8). Additional secondary measures of Patient Global Impression of Change (PGIC), King's PD Pain Scale...
INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
AbstractBackgroundContinuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively ma...
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms...
Background: Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce heal...
Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the Un...
Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the Un...
peer reviewedINTRODUCTION: Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percut...
Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojej...
INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
Introduction: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
Motor complications in Parkinson's disease (PD) are associated with long-term oral levodopa treatmen...
Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestin...
Introduction: The GLORIA registry included 375 advanced Parkinson’s disease (PD) patients and evalua...
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms...
Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by mo...
INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
AbstractBackgroundContinuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively ma...
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms...
Background: Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce heal...
Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the Un...
Background: Levodopa-carbidopa intestinal gel (LCIG; carbidopa-levodopa enteral suspension in the Un...
peer reviewedINTRODUCTION: Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percut...
Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojej...
INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
Introduction: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
Motor complications in Parkinson's disease (PD) are associated with long-term oral levodopa treatmen...
Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestin...
Introduction: The GLORIA registry included 375 advanced Parkinson’s disease (PD) patients and evalua...
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms...
Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by mo...
INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intesti...
AbstractBackgroundContinuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively ma...
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms...